Chul Kim

Honored to join @AMansfieldMD and Dr. Chris Nabel on a panel at The Thymic Carcinoma Center’s annual gala in Kansas City.

Thank you to the patients, caregivers, and advocates who shared their inspiring stories tonight. We have much more to do for people facing this rare cancer.

Remarkable advances in HER2-mutant NSCLC over the past few years. Great overview by Dr. @lungoncdoc.

Now 3 approved agents: 2 TKIs (both approved for 1L) and 1 ADC.

Key Qs: optimal sequencing, overcoming resistance, combination strategies.

Inspiring keynote by Dr. @ShirishGadgeel on the evolution of ALK-positive NSCLC management

A picture is worth a thousand words

Look at the dramatic response to crizotinib back in 2010

A powerful reminder of how targeted therapy has transformed lung cancer care.

#HenryFordLung

An excellent review of EGFR-mutant NSCLC by Dr. Qin.

Tx landscape continues to expand, with emerging data from SAFFRON on MET and the availability of sunvozertinib in the U.S.

More options bring greater opportunities but also increasingly complex clinical decision making.

#HenryFordLung

An outstanding lineup of faculty and presentations awaits at ITMIG-LALCA 2026!

One registration provides on-site access to both conferences.

Join us in São Paulo, Brazil, November 12–14, 2026!

Register here:
conferences.iaslc.org/e/itmig-lalca26

@IASLC @Itmig_society